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Abstract  
 
Objective: To analyze the change in health-related quality-of-life (HRQoL) in patients with 
Parkinson’s disease (PD) and to identify different classes of HRQoL decline.  
Methods: A longitudinal cohort study was performed to assess clinical parameters (unified PD 
rating scale, Beck Depression Inventory) and HRQoL data (EuroQol, Parkinson’s Disease 
Questionnaire [PDQ]-39) at baseline, 3, 6, 12, 24, and 36 months. A total of 145 patients with 
PD were consecutively recruited in the county of Northern Hessia, Germany, between January 
and June 2000. A latent growth mixture model was applied to analyse the heterogeneity in 
HRQoL trajectories.  
Results: We successfully applied latent mixture growth modeling in order to identify different 
classes of HRQoL trajectories in PD. Three growth models were developed and each resulted 
in a four-class model of distinct patterns using the generic EuroQol instruments’ outcomes 
(EuroQol-5 Dimensions and visual analogue scale) and the disease-specific PDQ- 39. The 
four classes were defined by individual trajectory characteristics. Classes one and two 
represented trajectories with moderate declines over 36 months, but with different initial 
intercepts. Class three consisted mainly of patients who passed away during the observation 
period and therefore had a large HRQoL decline. Class four was characterized by a low level 
of HRQoL at baseline and a significant subsequent decline.  
Conclusions: The findings provide a more elaborate understanding of the variability in 
HRQoL reduction in PD over time. The classification of different HRQoL subgroups may 
help to explain the response of PD patients to the natural history of the disease. Future 
research will enable the identification of HRQoL responder subgroups on different treatment 
regimens.    
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Introduction  
 
Health-related quality-of-life (HRQoL) has become a key concept in patient-relevant 
outcomes research. In the absence of biomarkers adequately describing the progression of 
Parkinson’s disease (PD), patient-relevant outcomes are required to ensure that treatments in 
fact provide substantial benefits and do not only represent physiological surrogates without 
any influence on the patients’ well-being. Disease- specific and generic HRQoL instruments 
have been developed and used to measure the subjective perception of disease, as well as the 
improvement or deterioration caused by therapeutic interventions [1– 4]. In cancer for 
instance, HRQoL measures are already tested for their prognostic value (e.g. [5,6]).  
 
For PD, several disease-specific instruments are available and have already been applied in 
randomized controlled trials as a response measure to therapy – the Parkinson’s disease 
quality-of-life questionnaire (PDQL) [7] and the 39-item Parkinson’s disease Questionnaire 
(PDQ-39) [8 – 11].  
 
The impairment of HRQoL by PD is well described in the literature. The progressive and 
chronic nature of PD suggests that HRQoL will decline during the course of the disease [2]. 
Several studies have reported an independent association of decreased HRQoL and more 
severe (Hoehn and Yahr) disease stages [12]. Furthermore, motor complications such as 
motor fluctuations, dyskinesias, dystonia, and freezing as well as non-motor complications 
such as dementia, depression, or psychosis considerably decrease HRQoL [13]. Because 
HRQoL is a concept that is based on the subjective impression of the patient, it seems 
probable that determinants of self-perception and differences in coping strategies of the 
patients, in combination with their clinical and socio-demographic characteristics, influence 
and determine the change in self-reported HRQoL [14]. Given the large number of influences 
on HRQoL that may vary between individuals and within individuals over time, much 
heterogeneity of HRQoL trajectories in patients with PD can be expected.  
 
When revisiting data from one of our own studies, we found that the individual trajectories for 
EQ-5D and PDQ-39 indeed showed remarkable heterogeneity for the 145 patients followed-
up for 36 months. The subjects had an almost constant or decreasing quality of life during 
follow-up (Fig. 1 [13]).  
 
In contrast with conventional methods that are used to analyze longitudinal repeated 
measures, such as analysis of variance, the latent mixture growth model provides a tool for 
modeling heterogeneity in the individual trajectories across time. The traditional analysis of 
variance approach is limited by its assumptions regarding missing data and the variance– 
covariance structure over time. In the analysis of variance with repeated measures, it is 
assumed that the variance and covariance of the outcome variable are equal over time. This 
assumption failed for our previous data [13] and the traditional analysis of variance model did 
not fit the data. The application of growth models (mixed effect models) does not have this 
stringent assumption about the covariance matrix over time, and provides a flexible approach 
for longitudinal data modeling. The inclusion of latent variables into the growth model allows 
for the modeling of heterogeneity in individual trajectories over time. The estimated latent 
classes are characterized by the homogeneous characteristics of subjects within classes and 
distinctive characteristics between classes. The latent mixture growth model can be 
interpreted as a combination of mixed-effects modeling and cluster analysis [15,16].  
 
In the current study, we used such models to examine longitudinal changes in HRQoL using 
generic as well as diseasespecific instruments. Our approach allows for the prediction of 
distinct classes of HRQoL trajectories based on changes over time and the estimation of the 
most likely class membership of each individual.   
 
Patients and Methods  
 
Study design  
 
A total of 145 patients (97 male; 48 female) with idiopathic PD were consecutively recruited 
in the county of North Hessia, Germany, between January and June 2000. A detailed 
description of the study was reported recently [13]. Briefly, study sites included the 
Outpatient Department for Movement Disorders, Department of Neurology, Philipps-
University Marburg (n=29), the Paracelsus Elena Clinic, Kassel (n=31), two office-based 
neurologists (n=40), and general practitioners (n=45). Each patient received a structured 
assessment of parkinsonian signs and neurological symptoms (such as freezing and gait 
disturbances) conducted by a movement disorders specialist and their medical history was 
documented. Idiopathic Parkinson’s disease was diagnosed according to the clinical criteria of 
the U.K. Parkinson’s disease Society Brain Bank [17]. Patients were examined at baseline 
(T0), at 3 months (T1), 6 months (T2), 12 months (T3), 24 months (T4), and 36 months (T5). 
The study was approved by the local ethics committee and all participants gave informed 
consent.  
 
Evaluation of HRQoL  
 
Patient-reported HRQoL was measured by the generic EuroQol instrument [18] and the 
Parkinson-specific questionnaire PDQ-39 [19,20]. The EuroQol is widely used in clinical and 
economic evaluations. It covers the domains of mobility, selfcare, usual activities, 
pain/discomfort, and anxiety/depression. A single utility index score (EQ-5D index) is 
calculated by applying a scoring algorithm [21]. The second part of the EuroQol is a visual 
analogue scale (EQ-VAS) that is used to mark the patient’s current health status on a scale 
ranging from 0 to 100. The PDQ-39 is a widely used, reliable, and valid PD-specific quality 
of life instrument. Thirty-nine items examine eight dimensions (“mobility,” “activities of 
daily living,” “emotional well-being,” “stigma,” “social support,” “cognition,” 
“communication,” and “bodily discomfort”) and provide a composite score. Higher values of 
the PDQ-39 sum score indicate a lower quality of life.  
 
Disease severity  
 
The disease severity in each patient was examined using the Hoehn and Yahr Scale [22] and 
the unified Parkinson’s disease Rating Scale (UPDRS) parts II–IV [23]. UPDRS II assesses 
activities of daily living (e.g. speech, falling, freezing), UPDRS III comprises a motor 
examination, including tremor, gait or rigidity, and UPDRS IV describes complications of 
therapy by means of a) dyskinesias; b) clinical fluctuations; and c) other complications.  
 
Depressive symptoms were assessed by the Beck Depression Inventory (BDI) [24]. This is a 
reliable and valid measure for use in patients with PD [25]. Higher scores indicate increased 
depressive symptoms. Cognitive impairment was measured using the Mini Mental State 
Examination (MMSE). A summary-score of less than 19 was rated as probable cognitive 
impairment [26].  
 
 
 
Statistical analysis  
 
The analysis was based on 145 patients who participated at baseline (BL). At the 36-month 
assessment, 23 patients were lost to follow-up because of death, individual reasons (n=22), a 
too-complex study protocol (n=8), admission into a nursing home (n=1) and other reasons 
(n=3), resulting in a sample of 88 patients.  
 
The missing values were estimated by full-information maximum-likelihood estimation 
assuming missing at random, which is a widely accepted method for handling missing data 
[27,28]. Twenty-three patients passed away during the 36-month follow-up, and the missing 
outcome values for these patients were imputed as zero (EuroQoL) or worst possible (PDQ-
39), which is, according to the instruments used, the value for the health state ‘death’ [18,19]. 
In addition, the last observations carried forward (LOCF) method and multiple imputation by 
chained equations (MICE) [29] were used to assess the sensitivity of the latent growth 
mixture model with respect to missing data modeling. The predictor variables HRQoL at 
previous assessment (e.g., BL is the previous assessment to 6-month follow-up), UPDRS III, 
UPDRS IV, BDI, and gender were applied in the MICE approach.  
 
We analyzed each HRQoL measure (EQ-5D, EQ-VAS, and PDQ-39) with a separate latent 
growth mixture model [16] to identify distinct groups with a common pattern of HRQoL 
trajectories. The growth factor (slope) was modeled using a piecewise linear function to 
capture different growth rates for the time intervals BL to 6 months, 6 months to 24 months, 
and 24 months to 36 months. The intercept parameter (estimated baseline value of the 
outcome) and the probability of class membership were adjusted for gender and baseline 
values of UPDRS III, UPDRS IV, and BDI scores in the final models (Fig. 2). A detailed 
mathematical presentation of latent growth mixture modeling is provided elsewhere [16,30].  
 
In the first step, a single-class model (classical analysis) was specified to investigate the 
overall growth function for quality of life over time. A mixture growth model with K latent 
classes (K=2,3, . . .) was formulated to study possible subgroups of patients characterized by 
class-specific intercepts and slopes in the second step. The number of classes K was chosen 
by considering the bootstrap likelihood ratio test (BLRT) [31], which provides a consistently 
performing model test.  
 
The standard errors of the model parameters (intercept and slope estimates) were estimated by 
applying a sandwich estimator [32] that took into account the clustered sampling design 
(patients were clustered within study centers). The parameters were estimated by maximum 
likelihood. Multiple sets of starting values were applied to avoid local solutions in the 
estimation procedure. The growth mixture models were estimated for the EQ-5D, EQ-VAS, 
and PDQ-39 in MPLUS 5.21 [33]. Characterization of the estimated latent classes and 
subsequent analysis were conducted using STATA 10.2 (Stata Corp., College Station, Texas, 
USA) [34].  
 
In more detail, patient’s clinical characteristics at baseline were compared across the 
estimated latent classes by linear regression models for dimensional variables (age, age at 
symptom onset, duration of disease, Hoehn & Yahr, UPDRS, BDI, MMSE) and logistic 
regression models for categorical variables (gender, gait disturbances, dyskinesias, falls, 
fluctuations).  
 
 
 
Results  
 
The mean age of the sample of 145 patients was 67.3 years old (95% CI: 65.7–68.8) with 48 
females (33.1%). The mean age of PD onset was 57.6 years old (95% CI: 55.6–59.6) and the 
mean duration of disease was 9.3 years (95% CI: 8.0 –10.5). According to the Hoehn and 
Yahr scale, 42.8% were stage I/II, 30.3% were stage III, and 26.9% were stage IV/V at 
baseline. The summary UPDRS (II–IV) score was 48.1 (95% CI: 42.6–53.5). The clinical 
characteristics of the study sample are reported in Table 1.  
 
Fifty-seven subjects were lost to follow-up by death (N=23) and other reasons for drop-out 
(N=34). Baseline characteristics by drop-out status are reported in Table 1, which can be 
viewed at: doi:10.1016/j.jval.2010.10.005. Subjects lost to follow-up by other reasons are 
comparable to subjects followed by the 36-month study period in baseline characteristics. 
Subjects who died during the study period are characterized by longer duration of Parkinson’s 
disease, higher UPDRS scores, and increased stages in the Hoehn and Yahr scale.  
 
Figure 1 depicts the unadjusted result of an ordinary growth model of the EQ-5D index as a 
single mean growth curve. The estimated mean of the EQ-5D index was 0.85 (95% CI: 0.79–
0.89) adjusted for UPDRS III, UPDRS IV, and BDI at baseline. It showed a nearly constant 
course from T0 to T2 (∆=0.01, 95% CI: -0.08–0.03) and a significant decrease in quality of 
life from T2 to T5 (T2–T4: ∆ = -0.06, 95% CI: -0.09 – -0.03 and T4–T5: ∆ = -0.05, 95% CI: -
0.09 – -0.01). Obviously, the individual trajectories are very heterogeneous. There are patients 
with growth rates that differ substantially from the estimated average trajectory. Thus, a latent 
growth curve model was applied to model this heterogeneity in the data.  
 
The fit for the two-class, three-class, four-class, and fiveclass models with UPDRS III, 
UPDRS IV, BDI, and gender-adjusted probabilities of class membership and intercept 
parameters is shown in Table 2. The four-class model was regarded as the most appropriate to 
describe the heterogeneity based on a) the comparison of fit indices (Table 2); b) the visual 
comparison of individual trajectories with the estimated unadjusted mean growth curve within 
class (Fig. 3); and c) the number of patients within a class (Table 3). For example, the five-
class model does not add information compared to the four-class model for the EQ-5D index 
(Table 2). It simply divides class 4 into two subclasses.  
 
The parameter estimates of the growth curves for the four latent classes of the EQ-5D index, 
EQ-VAS and PDQ-39 sum score are reported in Table 3 with the baseline value and 
probability of class membership adjusted for UPDRS III, UPDRS IV, and BDI. The first 
latent class included patients with a high EQ-5D index at baseline (β=0.99; 95% CI: 0.97–
1.00) and a non-significant decrease over time. There was a related pattern for the trajectories 
in class 2 except that the EQ-5D index at baseline was lower compared to class 1 (β=0.79; 
95% CI: 0.75–0.82). In contrast, patients in classes 3 and 4 had a high HRQoL (class 3: 
β=0.88; 95% CI: 0.82–0.95) or a moderate HRQoL (class 4: β=0.66; 95% CI: 0.60–0.71) at 
baseline and a significant decrease over time (Fig. 3).  
 
The baseline correlates of the estimated four classes for the EQ-5D index are reported in 
Table 4. Patients in class 1 were less impaired according to clinical characteristics (UPDRS 
(II–IV); sum score=27.9, 95% CI: 20.7–35.1; UPDRS III=20.2, 95% CI: 15.0–25.3; 60.7% in 
Hoehn and Yahr stages I and II) and had a short disease duration (mean=7.0 years, 95% CI: 
5.4–8.6) compared with the other classes. Classes 2 and 3 are comparable by clinical 
characteristics and HRQoL at baseline, whereas almost all patients in class 3 (N=7, 88%) 
passed away during the follow-up period resulting in a significant decrease in HRQoL over 
time. Latent classes 3 and 4 included patients who passed away during follow-up. The two 
classes differed in respect to the time of death and the mean HRQoL at baseline. Class 3 
included cases of death that occurred in later follow-up waves with a high HRQoL at baseline, 
whereas class 4 included cases that passed away in earlier stages of follow-up. Classes 2 and 3 
were comparable in baseline clinical and socio-demographic parameters. Detailed analyses 
are shown in Table 4, which presents the correlates for the estimated four-class model. 
Patients in class 4 are characterized by a high UPDRS (II–IV) sum score (mean=84.8, 95% 
CI: 73.4–96.2), a long disease duration (mean=14.4, 95% CI: 11.4–17.4) and were older 
(mean=73.9, 95% CI: 70.2–77.5).  
 
We also studied the EQ-VAS and the PD-specific quality of life measure PDQ-39. In both 
cases, the general growth mixture model also resulted in a four-class model (Table 2). The 
pattern of EQ-VAS and PDQ-39 was comparable to the EQ-5D index within latent classes 
(Table 3). The absolute agreement between the EQ-5D index and EQ-VAS latent classes was 
78.9%, resulting in a kappa of 0.6 (P < 0.001). More than 50% (56.3%) of the subjects were 
classified in the same latent class of the EQ-5D index and PDQ-39, yielding a kappa of 0.4 (P 
< 0.001).  
 
Discussion  
 
Latent longitudinal models of growth are increasingly being used in the analysis of patient-
reported outcomes in neurological diseases, e.g., in dementia [35,36] and multiple sclerosis 
[37].  
 
Our study is the first to apply the growth mixture modeling technique to longitudinal changes 
in HRQoL in patients with PD. We successfully determined four subgroups of patients that 
differed in their course of HRQoL across a 36-month study period. Interestingly, as outlined 
in an earlier communication, patients do not deteriorate in the first 6 months according to the 
PDQ-39 instrument and the EuroQol measures [13]. The trajectories in classes 1 and 2 did not 
show a considerable decline over the 3 years of the study, but had different initial intercepts. 
In comparison, patients in classes 3 and 4 experienced a substantial decrease in HRQoL 
following a lower initial status compared to classes 1 and 2. As expected, members of latent 
class 4, who showed the most severe trajectory, had a significantly longer duration of disease 
and higher UPDRS values. Nearly all patients (90%) in class 3 passed away during the 36-
month study, having a moderate quality of life at baseline followed by a large decline. 
Patients in class 4 were older and were characterized by a lower level of HRQoL and a low 
level of clinical parameters at baseline. Altogether, PD patients were split into patients with a 
decline in HRQoL (latent classes 3 and 4) and those with a stable HRQoL (latent classes 1 
and 2) over time.  
 
We developed three separate models for the HRQoL measures assessed in this study: 1) the 
EQ-5D index score; 2) the EQ-VAS score; and 3) the PDQ-39. Although all three models 
gave four latent classes, this fact must be interpreted with caution. Due to the absolute 
agreement between these measures in the assignment of class membership, we reason that 
there is also a high level of agreement regarding what is measured in terms of HRQoL and 
responsiveness to PD progression. However, the psychometric characteristics differ 
completely between the three scales [2]. Thus, a higher level of agreement would not 
necessarily be expected even if the statistical power were increased by larger sample sizes and 
the inclusion of more covariates. Latent growth modeling should be considered as an 
appropriate method when comparing the responsiveness of PD scales to change over time.  
 
The application of growth mixture modeling allows for considering the investigated outcome 
over time and for modeling unobserved heterogeneity among patients rather than considering 
a single growth rate. This method can detect changes in outcome measures not only in a group 
of patients, but also individual differences in changes in outcome rates among group 
members. The mixture model approach considers the fact that individuals within a certain 
population start and end at different points with regard to their HRQoL measures over the 
longitudinal study period [38]. The growth mixture models are used to detect subgroups of 
individuals by usage of a latent class membership variable [29]. In other words, growth 
mixture modeling investigates whether there is enough homogeneity in changes over time to 
allow the separation of classes of individuals who differ with regard to their baseline 
measures and rates of change over time.  
 
Although we carefully designed the analyses, there are several limitations to this study. The 
patients were consecutively enrolled in the participating study centers without a 
randomization protocol. However, this convenience sample could be considered to be 
representative for patients suffering from Parkinson’s disease in the region North Hessia, 
Germany. Furthermore, we present a latent general growth mixture model for HRQoL in a 
sample of 145 patients with Parkinson’s disease. The sample size might limit our approach as 
follows: 1) the baseline value (intercept) of HRQoL was adjusted for BDI, UPDRS III+IV, 
and gender (Fig. 2). With a larger sample size, additional covariates could have extended the 
modeling framework in terms of its predictive power from the intercept towards class 
membership. 2) It would have been possible to include time-varying covariates, since the 
change in HRQoL over time (slope) depends on the course of disease severity. Modeling was 
also conducted using time varying covariates BDI and UPDRS III+IV, but the algorithm for 
parameter estimation did not converge normally; and 3) the sample was characterized by a 
clustered design in terms of different recruitment settings. The introduction of a multilevel 
growth model would have provided an alternative for estimating standard errors accounting 
for the patients’ characteristics within study centers. This approach would also require a larger 
sample size. Thus, we conclude that a larger sample size would be necessary to obtain stable 
parameter estimates for a more complex model with time-varying covariates. Nevertheless, 
the sample size of this study was appropriate for robust parameter estimates and convergence 
of the estimation algorithm when using a growth mixture model with a small number of 
covariates [39].  
 
To test the robustness of our assumption about using the worst possible score in EuroQol and 
PDQ-39 for the 23 patients who passed away, we applied the last observation carried forward 
method (LOCF) and multiple imputations by chained equations (MICE). The latent growth 
mixture models for the EQ-5D index, EQ VAS, and PDQ-39 in the LOCF data resulted in a 
three-class solution based on fit indices. The main difference was the collapsing of class 3 and 
4 into a single class compared to the models reported in Table 3 (see Appendix Table 2 at 
doi:10.1016/j.jval.2010.10.005.  
 
This fact could be caused by the LOCF approach. The within-subject variance is reduced for 
patients with missing values imputed by the LOCF method, resulting in a constant course of 
HRQoL across follow-up for these patients. In contrast, the course of HRQoL across time is 
estimated in the other missing value models applied in this study. There are remarkable 
differences in the clinical characteristics at baseline between classes 3 and 4 of the model 
described in Table 3. Patients of the two classes differ significantly with respect to time of 
death, age, duration of disease and disease severity (Hoehn and Yahr, UPDRS). Application 
of the MICE approach for estimating the missing values resulted in a four-class solution 
comparable to the final model reported in Table 3.  
 
We cannot rule out the possibility that other covariates that were not included in the model 
may have influenced the HRQoL trajectories. In particular, non-motor symptoms – 
psychiatric complications, sleep disturbances, and autonomic disturbances – that are known to 
reduce HRQoL, were not considered. Interestingly, a recent latent variable model study 
classified PD patients into four latent classes according to psychiatric and cognitive 
functioning. Age, disease severity, and medication use predicted class membership [40]. 
Further extensions of this pilot study should assess and include these influences as well as 
comorbidities, which are shown to have an independent negative effect on therapy outcome 
and health-related quality-of-life [41,42].  
 
Previous studies that investigated changes in HRQoL over time in patients with PD using 
linear models assumed that individuals follow the same mean trajectory [10,13,43,44]. 
Conventional methods overlooked individual differences in changes, regarding them as 
random error [45]. Longitudinal studies of PD using observation periods of 2 years and more 
have shown deterioration in HRQoL-scores over time [10,43,44]. Shorter observation periods 
lead to inconsistent results [13].  
 
In conclusion, this study provides new information on the longitudinal development of 
HRQoL in patients with PD over a period of 36 months. Different classes or groups were 
identified with substantial differences in the evolution of HRQoL over time. Interestingly, 
there are groups of patients whose HRQoL remains stable over longer periods of time. The 
classification of HRQoL subgroups may help to explain the response of PD patients to the 
natural history of the disease. Future research is required to identify the potential responder 
subgroups in terms of HRQoL on different treatment regimens. This may also allow for more 
targeted and systematic PD therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Material  
 
Supplementary material associated with this article can be found, in the online version, at 
doi:10.1016/j.jval.2010.10.005.  
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